Sam Brusco, Associate Editor09.05.23
Dexcom has rolled out its G6 continuous, real-time glucose monitor (rt-CGM), which connects to Insulet’s Omnipod 5 with automated insulin delivery (AID), in Germany.
“For over a decade, Dexcom has been the sensor of choice for the development of AID systems. Dexcom has supported more than 50 studies around the world ranging from early academic projects to increasingly sophisticated trials in collaboration with industry partners, safely powering AID systems for over 1 million patient-years of cumulative use. Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” Alex Moussa, senior VP and GM of Dexcom EMEA & LATAM told the press.
Dexcom strengthens its position as its claimed “world’s most connected CGM” with the Dexcom G6 and Omnipod 5 AID system launch to type 1 diabetes patients in Germany. In a study published in Diabetes Care, Dexcom G6 with Omnipod 5 “significantly improved” time in range and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with type 1 diabetes.
“At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community. This launch gives Dexcom users in Germany another choice in automated insulin delivery systems, adding to the company’s existing insulin delivery collaborations with Tandem, Ypsomed, and CamDiab. We are delighted to see years of close collaboration with industry partners result in giving people with diabetes unparalleled choice, peace of mind and better clinical outcomes,” said Alexander Fröhlich, Decxom’s VP for Germany, Austria, Switzerland, and Slovenia.
The Dexcom CGM is also integrated with the Tandem t:slim X2 and Ypsomed mylife YpsoPump insulin pumps; digital health apps including Glooko, Happy Bob, and Sugarmate, and most recently, lifestyle devices from Garmin.
“For over a decade, Dexcom has been the sensor of choice for the development of AID systems. Dexcom has supported more than 50 studies around the world ranging from early academic projects to increasingly sophisticated trials in collaboration with industry partners, safely powering AID systems for over 1 million patient-years of cumulative use. Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” Alex Moussa, senior VP and GM of Dexcom EMEA & LATAM told the press.
Dexcom strengthens its position as its claimed “world’s most connected CGM” with the Dexcom G6 and Omnipod 5 AID system launch to type 1 diabetes patients in Germany. In a study published in Diabetes Care, Dexcom G6 with Omnipod 5 “significantly improved” time in range and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with type 1 diabetes.
“At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community. This launch gives Dexcom users in Germany another choice in automated insulin delivery systems, adding to the company’s existing insulin delivery collaborations with Tandem, Ypsomed, and CamDiab. We are delighted to see years of close collaboration with industry partners result in giving people with diabetes unparalleled choice, peace of mind and better clinical outcomes,” said Alexander Fröhlich, Decxom’s VP for Germany, Austria, Switzerland, and Slovenia.
The Dexcom CGM is also integrated with the Tandem t:slim X2 and Ypsomed mylife YpsoPump insulin pumps; digital health apps including Glooko, Happy Bob, and Sugarmate, and most recently, lifestyle devices from Garmin.